ABC Stock Overview
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£14.19|
|52 Week High||UK£17.60|
|52 Week Low||UK£10.14|
|1 Month Change||16.89%|
|3 Month Change||15.74%|
|1 Year Change||-5.59%|
|3 Year Change||29.12%|
|5 Year Change||41.90%|
|Change since IPO||3,421.09%|
Recent News & Updates
|ABC||GB Biotechs||GB Market|
Return vs Industry: ABC exceeded the UK Biotechs industry which returned -38.4% over the past year.
Return vs Market: ABC exceeded the UK Market which returned -12.6% over the past year.
|ABC Average Weekly Movement||5.0%|
|Biotechs Industry Average Movement||7.8%|
|Market Average Movement||5.6%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.9%|
Stable Share Price: ABC is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ABC's weekly volatility (5%) has been stable over the past year.
About the Company
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.
Abcam Fundamentals Summary
|ABC fundamental statistics|
Is ABC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABC income statement (TTM)|
|Cost of Revenue||UK£89.90m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.032|
|Net Profit Margin||2.08%|
How did ABC perform over the long term?See historical performance and comparison
Is ABC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ABC?
Other financial metrics that can be useful for relative valuation.
|What is ABC's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ABC's PS Ratio compare to its peers?
|ABC PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
PRTC PureTech Health
AVCT Avacta Group
OXB Oxford Biomedica
Price-To-Sales vs Peers: ABC is good value based on its Price-To-Sales Ratio (9.3x) compared to the peer average (21.5x).
Price to Earnings Ratio vs Industry
How does ABC's PE Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Sales vs Industry: ABC is good value based on its Price-To-Sales Ratio (9.3x) compared to the European Biotechs industry average (12.8x)
Price to Sales Ratio vs Fair Ratio
What is ABC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||9.3x|
|Fair PS Ratio||11.6x|
Price-To-Sales vs Fair Ratio: ABC is good value based on its Price-To-Sales Ratio (9.3x) compared to the estimated Fair Price-To-Sales Ratio (11.6x).
Share Price vs Fair Value
What is the Fair Price of ABC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ABC (£14.19) is trading below our estimate of fair value (£20.21)
Significantly Below Fair Value: ABC is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Abcam forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABC's forecast earnings growth (44.1% per year) is above the savings rate (0.9%).
Earnings vs Market: ABC's earnings (44.1% per year) are forecast to grow faster than the UK market (8.7% per year).
High Growth Earnings: ABC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ABC's revenue (13.7% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: ABC's revenue (13.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABC's Return on Equity is forecast to be low in 3 years time (13.6%).
Discover growth companies
How has Abcam performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABC has a large one-off loss of £45.1M impacting its June 30 2022 financial results.
Growing Profit Margin: ABC's current net profit margins (2.1%) are lower than last year (5.4%).
Past Earnings Growth Analysis
Earnings Trend: ABC's earnings have declined by 36% per year over the past 5 years.
Accelerating Growth: ABC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ABC had negative earnings growth (-54.9%) over the past year, making it difficult to compare to the Biotechs industry average (-16.7%).
Return on Equity
High ROE: ABC's Return on Equity (1%) is considered low.
Discover strong past performing companies
How is Abcam's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ABC's short term assets (£257.8M) exceed its short term liabilities (£203.8M).
Long Term Liabilities: ABC's short term assets (£257.8M) exceed its long term liabilities (£133.3M).
Debt to Equity History and Analysis
Debt Level: ABC's net debt to equity ratio (1.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ABC's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ABC's debt is well covered by operating cash flow (45.6%).
Interest Coverage: ABC's interest payments on its debt are well covered by EBIT (16x coverage).
Discover healthy companies
What is Abcam current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Abcam Dividend Yield vs Market|
|Market Bottom 25% (GB)||2.1%|
|Market Top 25% (GB)||6.0%|
|Industry Average (Biotechs)||2.2%|
|Analyst forecast in 3 Years (Abcam)||0%|
Notable Dividend: Unable to evaluate ABC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: ABC is not paying a notable dividend for the UK market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ABC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alan Hirzel (54 yo)
Mr. Alan Thomas Hirzel, BS, MS, MBA, has been the Chief Executive Officer of Abcam Plc since September 8, 2014 and its Executive Director since January 30, 2014. Mr. Hirzel served as the Chief Marketing Of...
CEO Compensation Analysis
|Alan Hirzel's Compensation vs Abcam Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||UK£3m||UK£630k|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||UK£2m||UK£615k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||UK£2m||UK£600k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||UK£2m||UK£492k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||UK£1m||UK£480k|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||UK£614k||UK£320k|
Compensation vs Market: Alan's total compensation ($USD3.58M) is above average for companies of similar size in the UK market ($USD2.71M).
Compensation vs Earnings: Alan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: ABC's management team is seasoned and experienced (6.8 years average tenure).
Experienced Board: ABC's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|04 Apr 22||BuyUK£8,748||Sally Crawford||Individual||609||UK£14.36|
|04 Apr 22||BuyUK£24,692||Giles F. Kerr||Individual||1,719||UK£14.36|
|04 Apr 22||BuyUK£67,281||Peter Allen||Individual||4,684||UK£14.36|
|04 Apr 22||BuyUK£43,623||Mara Aspinall||Individual||3,037||UK£14.36|
|04 Apr 22||BuyUK£22,753||Mark Capone||Individual||1,584||UK£14.36|
|04 Apr 22||BuyUK£14,637||Chien Ling Lee||Individual||1,019||UK£14.36|
|Owner Type||Number of Shares||Ownership Percentage|
|Employee Share Scheme||413,870||0.2%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Abcam plc's employee growth, exchange listings and data sources
- Name: Abcam plc
- Ticker: ABC
- Exchange: AIM
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: UK£3.245b
- Shares outstanding: 228.65m
- Website: https://www.abcam.com
Number of Employees
- Abcam plc
- Discovery Drive
- Cambridge Biomedical Campus
- CB2 0AX
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ABC||AIM (London Stock Exchange AIM Market)||Yes||Ordinary Shares||GB||GBP||Nov 2005|
|ABCZ.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Nov 2005|
|A8C1||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 2005|
|ABCM||NasdaqGS (Nasdaq Global Select)||ADS||US||USD||Oct 2020|
|ABCM N||BMV (Bolsa Mexicana de Valores)||ADS||MX||MXN||Oct 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/06 00:00|
|End of Day Share Price||2022/10/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.